Titre : Inhibiteur lupique de la coagulation

Inhibiteur lupique de la coagulation : Questions médicales fréquentes

Termes MeSH sélectionnés :

Interrupted Time Series Analysis
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Inhibiteur lupique de la coagulation : Questions médicales les plus fréquentes", "headline": "Inhibiteur lupique de la coagulation : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Inhibiteur lupique de la coagulation : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-16", "dateModified": "2025-04-11", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Inhibiteur lupique de la coagulation" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Inhibiteurs des facteurs de la coagulation sanguine", "url": "https://questionsmedicales.fr/mesh/D019774", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs des facteurs de la coagulation sanguine", "code": { "@type": "MedicalCode", "code": "D019774", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.113" } } }, "about": { "@type": "MedicalCondition", "name": "Inhibiteur lupique de la coagulation", "alternateName": "Lupus Coagulation Inhibitor", "code": { "@type": "MedicalCode", "code": "D016682", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Thomas Schmitz", "url": "https://questionsmedicales.fr/author/Thomas%20Schmitz", "affiliation": { "@type": "Organization", "name": "Pharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, D-53121, Bonn, Germany." } }, { "@type": "Person", "name": "Charlotte A Bäuml", "url": "https://questionsmedicales.fr/author/Charlotte%20A%20B%C3%A4uml", "affiliation": { "@type": "Organization", "name": "Pharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, D-53121, Bonn, Germany." } }, { "@type": "Person", "name": "Diana Imhof", "url": "https://questionsmedicales.fr/author/Diana%20Imhof", "affiliation": { "@type": "Organization", "name": "Pharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, D-53121, Bonn, Germany. Electronic address: dimhof@uni-bonn.de." } }, { "@type": "Person", "name": "Jeremy W Jacobs", "url": "https://questionsmedicales.fr/author/Jeremy%20W%20Jacobs", "affiliation": { "@type": "Organization", "name": "Department of Laboratory Medicine, Yale School of Medicine, 330 Cedar Street, New Haven, CT, 06520, USA. Jeremy.jacobs@yale.edu." } }, { "@type": "Person", "name": "Jiraphorn Issara-Amphorn", "url": "https://questionsmedicales.fr/author/Jiraphorn%20Issara-Amphorn", "affiliation": { "@type": "Organization", "name": "Medical Microbiology, Interdisciplinary and International Program, Graduate School, Chulalongkorn University, Bangkok, Thailand." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Fiscal austerity and municipal health spending: an interrupted time series study.", "datePublished": "2024-09-23", "url": "https://questionsmedicales.fr/article/39319934", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.11606/s1518-8787.2024058005772" } }, { "@type": "ScholarlyArticle", "name": "Advancing health information during interhospital transfer: An interrupted time series.", "datePublished": "2023-10-16", "url": "https://questionsmedicales.fr/article/37846028", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/jhm.13221" } }, { "@type": "ScholarlyArticle", "name": "The Impact of Customized Screening Intervals on the Burden of Drug-Drug Interaction Alerts: An Interrupted Time Series Analysis.", "datePublished": "2024-09-30", "url": "https://questionsmedicales.fr/article/39347841", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10916-024-02113-8" } }, { "@type": "ScholarlyArticle", "name": "Effect of COVID-19 lock down on teenage pregnancies in Northern Uganda: an interrupted time series analysis.", "datePublished": "2023-11-04", "url": "https://questionsmedicales.fr/article/37925395", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12978-023-01707-8" } }, { "@type": "ScholarlyArticle", "name": "Eviction filings during bans on enforcement throughout the COVID-19 pandemic: an interrupted time series analysis.", "datePublished": "2023-08-15", "url": "https://questionsmedicales.fr/article/37581748", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.17269/s41997-023-00813-1" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Facteurs biologiques", "item": "https://questionsmedicales.fr/mesh/D001685" }, { "@type": "ListItem", "position": 3, "name": "Inhibiteurs des facteurs de la coagulation sanguine", "item": "https://questionsmedicales.fr/mesh/D019774" }, { "@type": "ListItem", "position": 4, "name": "Inhibiteur lupique de la coagulation", "item": "https://questionsmedicales.fr/mesh/D016682" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Inhibiteur lupique de la coagulation - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Inhibiteur lupique de la coagulation", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-14", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Inhibiteur lupique de la coagulation", "description": "Comment diagnostiquer un inhibiteur lupique de la coagulation ?\nQuels tests sont utilisés pour le diagnostic ?\nQuels sont les signes cliniques associés ?\nLe diagnostic nécessite-t-il des antécédents médicaux ?\nPeut-on avoir un inhibiteur sans lupus ?", "url": "https://questionsmedicales.fr/mesh/D016682?mesh_terms=Interrupted+Time+Series+Analysis&page=4#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Inhibiteur lupique de la coagulation", "description": "Quels sont les symptômes courants ?\nLes symptômes varient-ils d'une personne à l'autre ?\nY a-t-il des symptômes spécifiques aux femmes ?\nLes symptômes peuvent-ils s'aggraver avec le temps ?\nPeut-on avoir des symptômes sans saignement ?", "url": "https://questionsmedicales.fr/mesh/D016682?mesh_terms=Interrupted+Time+Series+Analysis&page=4#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Inhibiteur lupique de la coagulation", "description": "Peut-on prévenir l'inhibiteur lupique ?\nQuels conseils de mode de vie peuvent aider ?\nLes femmes enceintes doivent-elles être surveillées ?\nY a-t-il des vaccinations recommandées ?\nComment gérer le stress pour prévenir les symptômes ?", "url": "https://questionsmedicales.fr/mesh/D016682?mesh_terms=Interrupted+Time+Series+Analysis&page=4#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Inhibiteur lupique de la coagulation", "description": "Quels traitements sont disponibles ?\nLes anticoagulants sont-ils toujours nécessaires ?\nY a-t-il des effets secondaires aux traitements ?\nLe traitement est-il à vie ?\nLes traitements sont-ils efficaces ?", "url": "https://questionsmedicales.fr/mesh/D016682?mesh_terms=Interrupted+Time+Series+Analysis&page=4#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Inhibiteur lupique de la coagulation", "description": "Quelles sont les complications possibles ?\nLes complications sont-elles fréquentes ?\nComment prévenir les complications ?\nLes complications peuvent-elles être graves ?\nY a-t-il des signes d'alerte pour les complications ?", "url": "https://questionsmedicales.fr/mesh/D016682?mesh_terms=Interrupted+Time+Series+Analysis&page=4#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Inhibiteur lupique de la coagulation", "description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque ?\nLes antécédents médicaux jouent-ils un rôle ?\nLe stress peut-il être un facteur de risque ?\nY a-t-il des facteurs environnementaux ?", "url": "https://questionsmedicales.fr/mesh/D016682?mesh_terms=Interrupted+Time+Series+Analysis&page=4#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer un inhibiteur lupique de la coagulation ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic se fait par des tests de coagulation et la détection d'anticorps spécifiques." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests de temps de céphaline activée (TCA) et les tests d'anticorps anti-cardiolipine sont courants." } }, { "@type": "Question", "name": "Quels sont les signes cliniques associés ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent des saignements anormaux et des thromboses, souvent sans cause apparente." } }, { "@type": "Question", "name": "Le diagnostic nécessite-t-il des antécédents médicaux ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les antécédents de lupus ou d'autres maladies auto-immunes sont importants." } }, { "@type": "Question", "name": "Peut-on avoir un inhibiteur sans lupus ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, il est possible d'avoir un inhibiteur lupique sans diagnostic de lupus, bien que rare." } }, { "@type": "Question", "name": "Quels sont les symptômes courants ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des saignements, des ecchymoses, et des douleurs thoraciques." } }, { "@type": "Question", "name": "Les symptômes varient-ils d'une personne à l'autre ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'intensité et la nature des symptômes peuvent varier considérablement entre les individus." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques aux femmes ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les femmes peuvent éprouver des symptômes liés à la grossesse, comme des complications thromboemboliques." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils s'aggraver avec le temps ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent s'aggraver, surtout sans traitement approprié." } }, { "@type": "Question", "name": "Peut-on avoir des symptômes sans saignement ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains patients peuvent présenter des symptômes thromboemboliques sans saignement." } }, { "@type": "Question", "name": "Peut-on prévenir l'inhibiteur lupique ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de méthode de prévention spécifique, mais un suivi médical régulier est conseillé." } }, { "@type": "Question", "name": "Quels conseils de mode de vie peuvent aider ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, peut aider." } }, { "@type": "Question", "name": "Les femmes enceintes doivent-elles être surveillées ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une surveillance étroite est nécessaire pour prévenir les complications pendant la grossesse." } }, { "@type": "Question", "name": "Y a-t-il des vaccinations recommandées ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Les vaccinations doivent être discutées avec un médecin, surtout pour les immunodéprimés." } }, { "@type": "Question", "name": "Comment gérer le stress pour prévenir les symptômes ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Des techniques de gestion du stress, comme la méditation, peuvent aider à réduire les symptômes." } }, { "@type": "Question", "name": "Quels traitements sont disponibles ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des anticoagulants et des immunosuppresseurs pour gérer les symptômes." } }, { "@type": "Question", "name": "Les anticoagulants sont-ils toujours nécessaires ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Pas toujours, leur nécessité dépend de la gravité des symptômes et des antécédents médicaux." } }, { "@type": "Question", "name": "Y a-t-il des effets secondaires aux traitements ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements peuvent avoir des effets secondaires, comme des saignements ou des infections." } }, { "@type": "Question", "name": "Le traitement est-il à vie ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Cela dépend de la réponse au traitement et de l'évolution de la maladie, souvent à long terme." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "La plupart des traitements sont efficaces pour contrôler les symptômes et prévenir les complications." } }, { "@type": "Question", "name": "Quelles sont les complications possibles ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des thromboses, des AVC et des problèmes cardiaques." } }, { "@type": "Question", "name": "Les complications sont-elles fréquentes ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Les complications peuvent survenir, mais leur fréquence dépend de la gestion de la maladie." } }, { "@type": "Question", "name": "Comment prévenir les complications ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Un traitement approprié et un suivi régulier peuvent aider à prévenir les complications." } }, { "@type": "Question", "name": "Les complications peuvent-elles être graves ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines complications peuvent être graves et nécessiter une intervention médicale urgente." } }, { "@type": "Question", "name": "Y a-t-il des signes d'alerte pour les complications ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des douleurs thoraciques ou des troubles neurologiques doivent alerter immédiatement." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent le sexe féminin, des antécédents familiaux et d'autres maladies auto-immunes." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque est plus élevé chez les jeunes femmes, généralement entre 15 et 45 ans." } }, { "@type": "Question", "name": "Les antécédents médicaux jouent-ils un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de maladies auto-immunes augmentent le risque d'inhibiteur lupique." } }, { "@type": "Question", "name": "Le stress peut-il être un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress peut exacerber les symptômes et augmenter le risque de complications." } }, { "@type": "Question", "name": "Y a-t-il des facteurs environnementaux ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à certains médicaments ou à des agents environnementaux peut être un facteur." } } ] } ] }

Sources (10000 au total)

Fiscal austerity and municipal health spending: an interrupted time series study.

To analyze the impact of the fiscal austerity policy (PAF) on health spending in Brazilian municipalities, considering population size and source of funds.... The interrupted time series method was used to analyze the effect of the PAF on total expenditure, resources transferred by the Federal Government, and own/state per capita resources allocated to heal... The results for the national average of municipalities show that the PAF had a negative impact on the level of total expenditure and own/state resources allocated to health in the first half of 2015, ... In general, the impact of the PAF on health financing in municipalities was immediate and based on the decrease in own/state resources allocated to health. In large municipalities, however, the impact...

Advancing health information during interhospital transfer: An interrupted time series.

Although the transfer of patients between acute care hospitals (interhospital transfer, IHT) is common, health information exchange (HIE) during IHT remains inadequate, with fragmented communication a... Study subjects include patients aged >18 transferred to the medical, cardiology, oncology, or intensive care unit (ICU) services at an 800-bed quaternary care hospital; and healthcare workers involved... We will track patient safety endpoints and clinician workflow burdens and ensure the protection of patient data throughout the study. We will disseminate our findings via the creation of a toolkit for...

The Impact of Customized Screening Intervals on the Burden of Drug-Drug Interaction Alerts: An Interrupted Time Series Analysis.

Fixed and broad screening intervals for drug-drug interaction (DDI) alerts lead to false positive alerts, thereby contributing to alert fatigue among healthcare professionals. Hence, we aimed to inves...

Effect of COVID-19 lock down on teenage pregnancies in Northern Uganda: an interrupted time series analysis.

Pregnancy and childbirth complications are the leading cause of death among girls aged 15-19 years globally, with low- and middle-income countries (LMICs) accounting for 99% of global maternal deaths ... Using interrupted time series analysis (ITS), sometimes known as quasi-experimental time series analysis. We constructed a time series of the first ANC service utilization records for girls aged 10-19... The teenage pregnancy trend before the lockdown was decreasing by - 0.203 pregnancies per month, but in the first month after the institution of the lockdown (March 20, 2020), there was an increase in... Teenage pregnancies increased during the lockdown. This slight increase depicted the impact of the pandemic on the teenage pregnancy trend associated with the COVID-19 outbreak. The government needs t...

Eviction filings during bans on enforcement throughout the COVID-19 pandemic: an interrupted time series analysis.

Bans on evictions were implemented to reduce the spread of COVID-19 and to protect vulnerable populations during a public health crisis. Our objective was to examine how three bans on eviction enforce... Data were derived from eviction application records kept by the Ontario Landlord and Tenant Board. We used segmented regression analysis to model changes in the average weekly filing rates for evictio... The average number of weekly L1 and L2 applications dropped by 67.5 (95% CI: 55.2, 79.9) and 31.7 (95% CI: 26.7, 36.6) filings per 100,000 rental dwellings, respectively, following the first ban on ev... Our findings suggest that while the first ban on eviction enforcement appeared to substantially reduce filing rates, subsequent bans were less effective and none of them eliminated eviction filings al...

Effect of the COVID-19 pandemic on maternal healthcare indices in Southern Iran: an interrupted time series analysis.

Epidemics are anticipated to influence the coverage of health services. We assessed the impact of the COVID-19 pandemic on maternal healthcare indices and care providers' performance.... 1801 maternal healthcare centres under the auspices of Shiraz University of Medical Sciences, Shiraz, Southern Iran.... Approximately 63 000 pregnant women.... In this prospective ecological study, interrupted time series analysis was used to model and compare the trend of maternal healthcare indices before and after the COVID-19 pandemic announcement.... The results showed a significant drop in count of preconception healthcare visits, first routine laboratory tests, first trimester prenatal care, first trimester sonography, prenatal screening for bir... Using ecological data during the COVID-19 pandemic era, we observed a 'level change and slope change' as the major pattern of interruption of maternal healthcare coverage, indicating a possible indire...

Evaluation of the impact of the COVID-19 pandemic on a smoking cessation service in Derbyshire: An interrupted time series analysis.

Data published early in the COVID-19 pandemic suggested that smokers infected with SARS-CoV-2 were more likely to need hospital treatment or die than non-smokers, and thus this was seen as a motivator... Interrupted time series analysis to investigate the impact of COVID-19, and the shift to remote delivery of smoking cessation support, on the number of smokers who accessed cessation support with LLBD... 11,393 episodes of smoking cessation support were opened with LLBD between 01 January 2018 and 31 December 2021. The weekly count of all outcomes was increasing prior to the date when LLBD converted t... The COVID-19 pandemic, and associated shift to remote delivery of smoking cessation support by LLBD, had no substantial sustained overall impact on measures of smoking cessation service activity and s...

Suicide mortality following the implementation of tobacco packaging and pricing policies in Korea: an interrupted time-series analysis.

To prevent tobacco use in Korea, the national quitline number was added to tobacco packages in December 2012, tobacco prices were raised by 80% in January 2015, and graphic health warning labels were ... Monthly mortality from suicide was obtained from Cause-of-Death Statistics in Korea from December 2007 to December 2019. Interrupted time-series analysis was performed using segmented Poisson regressi... Suicide mortality was 20 per 1,000,000 in December 2007 and showed a downward trend over the study period. After the implementation of tobacco packaging and pricing policies, suicide mortality immedia... The findings of this study provide new evidence for an association between tobacco control policies and deaths by suicide. An array of effective tobacco control policies should be considered for preve...